2021
Gender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment
Biondi BE, Frank CA, Forray A, Springer SA. Gender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment. Substance Use & Addiction Journal 2021, 42: 905-911. PMID: 33750285, PMCID: PMC8455717, DOI: 10.1080/08897077.2021.1900984.Peer-Reviewed Original ResearchConceptsSubstance use disordersOpioid use disorderMedication treatmentUse disordersAlcohol use disorderMental health severityXR-NTXAntiretroviral therapyDouble-blind placebo-controlled trialExtended-release naltrexone treatmentExtended-release naltrexonePlacebo-controlled trialCriminal justice-involved personsHealth severityGender differencesCocaine use disorderDrug use severityJustice-involved personsClinical characteristicsART adherenceNaltrexone treatmentTreatment outcomesHigh prevalenceCocaine useHIVA Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes
McNamara KF, Biondi BE, Hernández-Ramírez RU, Taweh N, Grimshaw AA, Springer SA. A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes. Open Forum Infectious Diseases 2021, 8: ofab289. PMID: 34430670, PMCID: PMC8378589, DOI: 10.1093/ofid/ofab289.Peer-Reviewed Original ResearchOpioid use disorderHepatitis C virusInfectious disease outcomesViral suppressionUse disordersVirologic responseDisease outcomeHuman immunodeficiency virus (HIV) viral suppressionNew hepatitis B virus (HBV) infectionsHepatitis B virus infectionGreater ART adherenceTreatment of OUDB virus infectionHIV viral suppressionAntiretroviral therapy adherenceImpact of medicationHCV reinfectionART adherenceMedication treatmentTherapy adherenceHIV treatmentInfectious disease epidemicsC virusOpioid epidemicTreatment outcomes
2020
A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?
Biondi BE, Zheng X, Frank CA, Petrakis I, Springer SA. A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success? American Journal On Addictions 2020, 29: 249-267. PMID: 32346932, PMCID: PMC7377168, DOI: 10.1111/ajad.13051.Peer-Reviewed Original ResearchConceptsUrine drug testsOpioid usePrimary outcomeOpioid use disorderTreatment studiesTreatment successUse disordersMedication treatment studiesOpioid treatment outcomesDifferent primary outcomesClinical trialsOpioid outcomesTreatment outcomesInclusion criteriaOutcome measuresLiterature reviewDrug testsOutcomesDisordersTreatmentReviewMedicationsMOUDStudyClinicians
2019
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV
Fanucchi L, Springer SA, Korthuis PT. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Current HIV/AIDS Reports 2019, 16: 1-6. PMID: 30684117, PMCID: PMC6420833, DOI: 10.1007/s11904-019-00436-7.Peer-Reviewed Original ResearchConceptsOpioid use disorderExtended-release naltrexoneHIV treatment outcomesHIV viral suppressionViral suppressionUse disordersAntiretroviral therapyTreatment outcomesCurrent US opioid epidemicOptimal HIV treatment outcomesUS opioid epidemicOverall mortalityHIV outbreakHIV treatmentOpioid epidemicMOUDHIVMedicationsDisordersNaltrexoneDelivery characteristicsTherapyTreatmentIncarcerated settingsOutcomes
2015
HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study
Vagenas P, Zelenev A, Altice FL, Di Paola A, Jordan AO, Teixeira PA, Frew PM, Spaulding AC, Springer SA. HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study. AIDS Care 2015, 28: 22-31. PMID: 26275122, PMCID: PMC4713253, DOI: 10.1080/09540121.2015.1062464.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAnti-HIV AgentsBlack or African AmericanBlack PeopleContinuity of Patient CareHealth Services AccessibilityHealthcare DisparitiesHIV InfectionsHomosexuality, MaleHumansInsurance, HealthKaplan-Meier EstimateMalePrisonersPrisonsRacial GroupsTreatment OutcomeYoung AdultConceptsBlack MSMHIV healthcare providersHIV treatment outcomesDisease management interventionsHIV/AIDS epidemicYoung Black MSMImpact of ageNon-black MSMHigher infection rateYoung HIVTreatment outcomesLarge cohortWorst HIVHIVHealth outcomesJail detaineesMale subgroupHealthcare providersInfection rateMulti-site studyMSMAIDS epidemicMenBlack menIntervention
2014
HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study
Meyer JP, Cepeda J, Springer SA, Wu J, Trestman RL, Altice FL. HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study. The Lancet HIV 2014, 1: e77-e84. PMID: 25473651, PMCID: PMC4249702, DOI: 10.1016/s2352-3018(14)70022-0.Peer-Reviewed Original ResearchViral suppressionHIV treatment outcomesInhibitor-based regimensObservational cohort studyHIV viral suppressionART regimenCohort studyRetrospective cohortPrimary outcomeViral loadPsychiatric comorbidityTreatment outcomesIdentification of individualsHIVJail detaineesLaboratory databaseTreatment potencyDrug abuseRNA copiesNational InstitutePrison releasePublic healthBlack menIncarceration periodsOutcomesDesign and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community
Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials 2014, 39: 256-268. PMID: 25240704, PMCID: PMC4283549, DOI: 10.1016/j.cct.2014.09.002.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentPlacebo-controlled trialXR-NTXAgonist treatmentOpioid dependenceTreatment outcomesPoor HIV treatment outcomesOpioid treatment outcomesOpioid-dependent prisonersExtended-release naltrexoneHIV treatment outcomesHIV transmission riskEvidence-based treatmentsCriminal justice settingsEarly acceptabilityStudy medicationFirst injectionStudy acceptabilityHIVTotal referralsJail detaineesCommunity settingsTransmission riskDrug relapseHigh internal validity
2013
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community
Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials 2013, 37: 209-218. PMID: 24384538, PMCID: PMC3992862, DOI: 10.1016/j.cct.2013.12.006.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialHIV treatment outcomesTreatment outcomesCriminal justice system (CJS) populationsPoor antiretroviral therapy (ART) adherenceAlcohol useExtended-release naltrexoneAntiretroviral therapy adherenceMedication-assisted therapyPrevention of relapseAlcohol use disorderSexual risk-taking behaviorsAlcohol-dependent personsXR-NTXHigh morbidityTherapy adherenceAlcohol relapseHigh prevalenceStudy participationEligibility criteriaUse disordersHIVRelapseHazardous drinkingNaltrexonePartner violence and health among HIV-infected jail detainees
Meyer JP, Wickersham JA, Fu JJ, Brown SE, Sullivan TP, Springer SA, Altice FL. Partner violence and health among HIV-infected jail detainees. International Journal Of Prison Health 2013, 9: 124-141. PMID: 24376468, PMCID: PMC3873166, DOI: 10.1108/ijph-03-2013-0011.Peer-Reviewed Original ResearchConceptsIntimate partner violenceSubstance use disordersHIV treatment outcomesHealthcare utilizationPartner violenceTreatment outcomesJail detaineesIPV exposureEffects of IPVHIV secondary preventionPost-release interventionsUntreated mental disordersDepth qualitative interviewsLifetime IPV exposureForms of childhoodHigher alcohol use severityCriminal justice populationsAlcohol use severityViolence reductionCJ populationsTime of incarcerationHIV diagnosisSecondary preventionAdulthood abuseQualitative interviewsContribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail
Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail. AIDS And Behavior 2013, 17: 118-127. PMID: 23673792, PMCID: PMC3818019, DOI: 10.1007/s10461-013-0506-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlcohol DrinkingAnti-Retroviral AgentsComorbidityCross-Sectional StudiesFemaleHIV InfectionsHumansLogistic ModelsMaleMedication AdherenceMiddle AgedPrisonersPrisonsSocioeconomic FactorsSubstance Abuse, IntravenousSubstance-Related DisordersTreatment OutcomeUnited StatesYoung AdultConceptsAntiretroviral medication adherenceSubstance use disordersMedication adherenceUse disordersEvidence-based drug treatmentHIV care providersHIV treatment engagementHIV treatment outcomesMedication-assisted therapyMulti-faceted interventionPaucity of evidenceDrug use severityAntiretroviral therapyPoor outcomePsychiatric comorbidityHIV treatmentTreatment outcomesDrug treatmentCare providersJail detaineesTreatment engagementUS sitesSubstance useVulnerable populationsUse severity
2012
Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLOS ONE 2012, 7: e38335. PMID: 22719814, PMCID: PMC3365007, DOI: 10.1371/journal.pone.0038335.Peer-Reviewed Original ResearchConceptsMaximum viral suppressionOpioid dependenceViral suppressionGlobal health qualityMaximal viral suppressionHIV treatment outcomesBuprenorphine/naloxoneCopies/mLChronic relapsing diseaseDSM-IV criteriaAntiretroviral therapyOpioid useProspective trialProspective studyRelapsing diseaseOpioid dependentsTreatment outcomesHIV-1HIVNLXHealth qualityTherapyWeeksSuppressionGroup
2011
Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes
Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials 2011, 33: 436-444. PMID: 22101218, PMCID: PMC3268833, DOI: 10.1016/j.cct.2011.11.002.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesSelf-administered therapyAntiretroviral therapyTreatment outcomesViral loadEvidence-based adherence interventionsPoor HIV treatment outcomesGenotypic resistance testingMedication-assisted treatmentDSM-IV criteriaAlcohol use disorderCase management servicesViral suppressionPrimary outcomeOpioid dependenceAdherence interventionsCD4 testingIntervention periodStudy groupEligibility criteriaUse disordersIntervention monthDrug usersAdverse HIVHIVPublic Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components
Springer SA, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Diseases 2011, 53: 469-479. PMID: 21844030, PMCID: PMC3156144, DOI: 10.1093/cid/cir446.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCombination antiretroviral therapyPublic health implicationsTreatment outcomesPoor HIV treatment outcomesHuman immunodeficiency virus (HIV) infectionImmunodeficiency syndrome prevalenceHIV treatment outcomesImmunodeficiency virus infectionHealth implicationsMental illness treatmentSubstance use disordersCase management servicesAntiretroviral therapySecondary preventionSyndrome prevalenceTransitional careImmunological outcomesCriminal justice populationsVirus infectionIllness treatmentUse disordersHIVMental illnessAlcohol useMedical insurance
2010
HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners
Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. The American Journal Of Drug And Alcohol Abuse 2010, 37: 12-21. PMID: 21171933, PMCID: PMC3070290, DOI: 10.3109/00952990.2010.540280.BooksConceptsAlcohol use disorderHIV treatment outcomesTreatment outcomesAlcohol dependencePoor HIV treatment outcomesRole of pharmacotherapyRelationship of HIVHIV risk behaviorsBetter treatment outcomesEvidence-based treatmentsAntiretroviral therapySignificant morbidityTherapeutic optionsPoor adherenceAlcohol abuseHIVUse disordersHIV cycleCommunity settingsRisk behaviorsAlcohol usePrimary articlesImproved treatmentVulnerable populationsNaltrexoneA systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization
Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug And Alcohol Dependence 2010, 112: 178-193. PMID: 20705402, PMCID: PMC2997193, DOI: 10.1016/j.drugalcdep.2010.06.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHealth care utilizationHIV treatment outcomesAlcohol use disorderPoor HIV treatment outcomesCare utilizationTreatment outcomesAntiretroviral therapyUse disordersImpact of AUDHealth service utilizationHIV/AIDSCD4 countHIV statusMedication adherenceService utilizationDATA SYNTHESISAnimal studiesElectronic databasesSystematic reviewAlcohol useTherapyPrimary articlesGoogle ScholarAdherenceOutcomesImproved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment
Springer SA, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment. Journal Of Urban Health 2010, 87: 592-602. PMID: 20177974, PMCID: PMC2900572, DOI: 10.1007/s11524-010-9438-4.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySubstance abuse treatment outcomesTreatment outcomesNon-detectable viral loadOpioid treatment outcomesBuprenorphine/naloxoneDSM-IV criteriaAgonist therapyAntiretroviral therapyCD4 countOpioid cravingAdverse eventsBuprenorphine treatmentOpioid dependenceViral loadUrine testingHIVTherapyVulnerable populationsWeeksOutcomesNLXTrialsInductionLikert scale